Search hospitals > Utah > Farmington

Farmington Health Center

Claim this profile
Farmington, Utah 84025
Global Leader in Breast Cancer
Global Leader in Breast cancer
Conducts research for Pancreatic Cancer
Conducts research for Cancer
Conducts research for Prostate Cancer
71 reported clinical trials
21 medical researchers
Photo of Farmington Health Center in FarmingtonPhoto of Farmington Health Center in FarmingtonPhoto of Farmington Health Center in Farmington

Summary

Farmington Health Center is a medical facility located in Farmington, Utah. This center is recognized for care of Breast Cancer, Breast cancer, Pancreatic Cancer, Cancer, Prostate Cancer and other specialties. Farmington Health Center is involved with conducting 71 clinical trials across 198 conditions. There are 21 research doctors associated with this hospital, such as Heloisa Soares, Theresa Werner, MD, Howard Colman, MD, PhD, and Vaia Florou.

Area of expertise

1Breast Cancer
Global Leader
Farmington Health Center has run 19 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
HER2 positive
ER positive
2Breast Cancer
Global Leader
Farmington Health Center has run 16 trials for Breast cancer. Some of their research focus areas include:
HER2 negative
HER2 positive
ER negative

Top PIs

Clinical Trials running at Farmington Health Center

Esophageal cancer
Breast Cancer
Gastric cancer
Esophageal Adenocarcinoma
Esophageal Cancer
Stomach Cancer
Small Cell Lung Cancer
Pancreatic Carcinoma
Gastroesophageal Junction Adenocarcinoma
Breast cancer
Image of trial facility.

Chemotherapy + Radiotherapy

for Esophageal and Gastric Cancer

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Farmington Health Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security